Gene therapy -: designer promoters for tumour targeting

被引：178

作者：

Nettelbeck, DM ^{[1
]}

Jérôme, V ^{[1
]}

Müller, R ^{[1
]}

机构：

[1] Univ Marburg, Inst Mol Biol & Tumor Res, IMT, D-35033 Marburg, Germany

来源：

TRENDS IN GENETICS | 2000年 / 16卷 / 04期

关键词：

D O I：

10.1016/S0168-9525(99)01950-2

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

One of the biggest challenges facing cancer therapy is to generate tumour-specific treatment strategies. Gene therapy hopes to achieve this by directing the activity of therapeutic genes specifically to the sites of disease. Of paramount importance for the success of this approach is the availability of tumour-specific delivery systems: both the transductional targeting of the vector vehicle and the restriction of transgene expression to the tumour are promising strategies towards this goal. This review will focus on the recent achievements in the field of transcriptional targeting and the different strategies to improve or design promoters with the desired specificities.

引用

页码：174 / 181

页数：8

共 73 条

[1] Complementary adenoviral vectors for oncolysis [J].

Alemany, R ;

Lai, SP ;

Lou, YC ;

Jan, HY ;

Fang, XM ;

Zhang, WW .

CANCER GENE THERAPY, 1999, 6 (01) :21-25

[2] In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector [J].

Arbuthnot, PB ;

Bralet, MP ;

LeJossic, C ;

Dedieu, JF ;

Perricaudet, M ;

Brechot, C ;

Ferry, N .

HUMAN GENE THERAPY, 1996, 7 (13) :1503-1514

[3]

BILBAO G, 1998, TUMOR TARGET, V3, P59

[4] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].

Bischoff, JR ;

Kim, DH ;

Williams, A ;

Heise, C ;

Horn, S ;

Muna, M ;

Ng, L ;

Nye, JA ;

SampsonJohannes, A ;

Fattaey, A ;

McCormick, F .

SCIENCE, 1996, 274 (5286) :373-376

[5] Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach [J].

Brand, K ;

Loser, P ;

Arnold, W ;

Bartels, T ;

Strauss, M .

GENE THERAPY, 1998, 5 (10) :1363-1371

[6] Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter [J].

Cao, G ;

Kuriyama, S ;

Gao, J ;

Kikukawa, M ;

Cui, L ;

Nakatani, T ;

Zhang, X ;

Tsujinoue, H ;

Pan, X ;

Fukui, H ;

Qi, Z .

GENE THERAPY, 1999, 6 (01) :83-90

[7] Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter [J].

Chen, L ;

Chen, DS ;

Manome, Y ;

Dong, YH ;

Fine, HA ;

Kufe, DW .

JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (06) :2775-2782

[8] GENE-THERAPY FOR CANCER [J].

CULVER, KW ;

BLAESE, RM .

TRENDS IN GENETICS, 1994, 10 (05) :174-178

[9] Targeting gene expression to hypoxic tumor cells [J].

Dachs, GU ;

Patterson, AV ;

Firth, JD ;

Ratcliffe, PJ ;

Townsend, KMS ;

Stratford, IJ ;

Harris, AL .

NATURE MEDICINE, 1997, 3 (05) :515-520

[10] Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma [J].

Diaz, RM ;

Eisen, T ;

Hart, IR ;

Vile, RG .

JOURNAL OF VIROLOGY, 1998, 72 (01) :789-795

← 1 2 3 4 5 6 7 8 →